This site is intended for healthcare professionals

Long-term tildrakizumab efficacy in the ReSURFACE psoriasis study

Bookmark
As an author on the recent publication detailing 3-year data with the IL-23p19 inhibitor tildrakizumab, can you describe the extent to which efficacy was maintained over the three years?